EUCTR2019-000935-15-FR进行中（未招募）1 期
CIRCULATE- CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II - PRODIGE 70-CIRCULATE
Centre Hospitalier Universitaire (CHU) de Dijon0 个研究点目标入组 1,980 人开始时间: 2019年6月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,980
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed written informed consent obtained prior to any study specific procedures
- •- Age = 18 years and = 75 years
- •- Histologically confirmed stage II colon and high rectum adenocarcinoma excluding low and medium rectal cancers (tumor location = 12 cm from the anal verge by endoscopy and/or above the peritoneal reflection at surgery are still eligible), without gross or microscopic evidence of residual disease after surgery with curative intent. Pathology report must be faxed to CRGA just after patient’s registration.
- •- No metastatic disease on CT-Scan and/or liver MRI done within 3 months before randomization.
- •- Randomization planned up to 7 weeks after curative R0 resection
- •- WHO performance Status < 2
- •- No prior chemotherapy for colo-rectal cancer
- •- No prior abdominal or pelvic irradiation for colo-rectal cancer
- •- Life expectancy of = 5 years
- •- Negative pregnancy test performed = 7 before registration (for women of childbearing age)
- •- Adequate haematological function:with neutrophils = 1,500 /mm3, platelet count = 100,000/mm3, hemoglobin = 9 g/dL (5,6 mmol/l)
- •- Total bilirubin = 1.5 x ULN (upper limit of normal)
- •- ASAT and ALAT = 2.5 x ULN
- •- Alkaline phosphatase = 2.5 x ULN
- •- Serum creatinine = 120 µmol/L or creatinine clearance =50 ml/min according MDRD (Modification of Diet in Renal Disease)
- •- Carcinoembryogenic antigen (CEA) = 1.5 x ULN after surgery (during screening period)
- •- Patient affiliated to a social security system
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1800
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 180
排除标准
- •- T4b tumors
- •- Peripheral neuropathy > grade 1
- •- Comorbidity influencing the 5 year patients’ survival including clinically relevant cardiovascular disease
- •- Ischemic myocardial infarction in the last year and/or unstable ischemic cardiopathy,
- •- Participation to another interventional study for postoperative therapy
- •- Known DPD deficiency (for patients afterward randomized in chemotherapy arm, DPD deficiency will be mandatory tested prior to 5FU administration)
- •- Legal incapacity or physical, psychological social or geographical status interfering with the patient's ability to sign the informed consent or to finish the study
- •- Medical history of other concomitant or previous malignant disease, except adequately treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of the skin, or cancer in complete remission for = 5 years,
- •- Lack of effective contraception in patients (men and/or women) of childbearing age, pregnant or breastfeeding women. Women of childbearing potential should agree to use a method of contraception during treatment of the trial and at least 4 months after discontinuation of oxaliplatin therapy and at least 30 days after discontinuation of 5-fluorouracil. Men must agree to use a method of contraception during treatment and at least 6 months after stopping oxaliplatin therapy and at least 3 months after stopping 5-fluorouracil.
研究者
相似试验
招募中
不适用
Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patientsmetastatic prostate cancerNL-OMON24467Erasmus Medical Center95
招募中
不适用
Circulating Tumour DNA as a Sensitive and Specific Marker of Response to Therapy and of Occult Disease in Colorectal CancerPatients with resectable colorectal cancer liver metastasesCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12612000345886udwig Institute for Cancer Research100
进行中（未招募）
1 期
Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217Colon cancer stage IIMedDRA version: 21.0Level: PTClassification code 10009954Term: Colon cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10038049Term: Rectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003691-12-DETechnische Universität Dresden4,812
招募中
3 期
Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE), AIO-KRK-0217DRKS00018695Technische Universität Dresden4,812
招募中
1 期
CIRCULATEcolon cancer stage II, rectal cancer stage IIMedDRA version: 21.0Level: PTClassification code: 10009954Term: Colon cancer stage II Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10038049Term: Rectal cancer stage II Class: 100000004864CTIS2023-506715-18-00Technische Universitat Dresden140